Restore your bladder, LOSE YOUR MIND: Oxybutynin bladder drug found to drastically increase the risk of dementia
(Natural News) A common drug for urinary incontinence may increase the risk of dementia, according to a recent study. Researchers said the bladder drug oxybutynin, which helps relieve muscle spasms that trigger overactive bladder syndrome, was consistently shown to raise the risk of dementia and impaired cognitive function when taken orally. According to the study, 16... (Source: NaturalNews.com)
Source: NaturalNews.com - August 7, 2018 Category: Consumer Health News Source Type: news

Nuvectra Suffers Painful Stock Drop After Regulatory Update
A company that spun out of Greatbatch in 2016 experienced a painful drop in its stock price Monday after updating investors on its regulatory progress for a sacral neuromodulation (SNM) system designed to treat chronic urinary retention and the symptoms of overactive bladder. Plano, TX-based Nuvectra said FDA has asked for additional information related to any modifications or changes to its Virtis device, labeling, and manufacturing as well as clarifications of data related to MRI. The company also has been asked to submit clinical study data to the European Union regulatory before it can recommend CE mark ...
Source: MDDI - July 3, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

18 years old and still wetting the bed: Teenager speaks out about his lifelong bladder problem
Seb Cheer, 18, from Cardiff, has suffered with an overactive bladder for his whole life but, now at Leeds University, he is encouraging other young people to discuss the condition. (Source: the Mail online | Health)
Source: the Mail online | Health - June 29, 2018 Category: Consumer Health News Source Type: news

BlueWind Medical Receives FDA Approval for Pivotal Trial Design of RENOVA iStim(TM) Implantable Tibial Nerve Neuromodulator for Overactive Bladder
HERZLIYA, Israel, June 14, 2018 -- (Healthcare Sales & Marketing Network) -- BlueWind Medical, a developer of a miniature wireless neurostimulation platform, for the treatment of multiple clinical indications, announced today that the US Food and Drug Adm... Devices, Urology, Neurology, FDA BlueWind Medical, RENOVA iStim, overactive bladder, Tibial Stimulation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Foods for bladder health
Having an overactive bladder can be a very challenging condition, but there are many ways in which people can improve their symptoms. These include monitoring the foods and drinks that they consume, as well as avoiding alcohol, caffeine, and spicy foods. Learn more about the overactive bladder diet here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 18, 2018 Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news

Neuromodulation Continues to be Activity Hotbed
The Neuromodulation market is rapidly growing and has become host to many medtech companies. StimGuard is the latest firm to make significant moves in the space, as it has received CE mark for a wireless neuromodulation device to treat chronic symptoms of overactive bladder. The Pompano Beach, Fla.-based company said its StimGuard would be available in Europe in the summer of 2018. “A wireless system that enables urologists to inject such a clinically proven therapy represents a shift in the field where there has only been one option for over 15 years,” Karl-Dietrich Sievert MD, PhD, professor and co-chairman o...
Source: MDDI - May 18, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

StimGuard wins CE Mark for SNS overactive bladder treatment
StimGuard said today it won CE Mark approval in the European Union for its sacral nerve stimulator designed to treat intractable symptoms of overactive bladder, with plans to launch the device in the EU this summer. The Pompany Beach, Fla.-based company touted that the StimGuard SNS system can be implanted through a needle without a surgery, as the device is 95% smaller than other similar sacral nerve stimulation devices on the market. The system uses an Apple iPad as a programming console, the company added. “A wireless system that enables urologists to inject such a clinically proven therapy represents a shift...
Source: Mass Device - May 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Neuromodulation/Neurostimulation Regulatory/Compliance StimGuard Source Type: news

FDA Approves Mirabegron, Solifenacin Combo for OAB FDA Approves Mirabegron, Solifenacin Combo for OAB
The FDA has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate for the treatment of overactive bladder (OAB).FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2018 Category: Consumer Health News Tags: Urology News Alert Source Type: news

FDA Approves Supplemental New Drug Application for Myrbetriq (mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms
TOKYO, May 7, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 7, 2018 Category: Drugs & Pharmacology Source Type: news

Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
Cornelia Haag-Molkenteller, former VP and Therapeutic Area Head, Clinical Development, for Urology, Women's Health, and Internal Medicine at Allergan, joins as Chief Medical Officer Michael McFadden, former SVP for Commercial at Avanir, joins as Chief C... Biopharmaceuticals, Urology, Personnel Urovant Sciences, Vibegron, overactive bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 24, 2018 Category: Pharmaceuticals Source Type: news

Laborie Medical closes $214m Cogentix buy
Laborie Medical Technologies said today that it closed the $214 million acquisition of Cogentix Medical (NSDQ:CGNT). With about 85% of the urology and gynecology device maker’s shares tendered over the weekend, meeting the minimum tender requirement, the stage was set for the deal to close today. The $3.85-per-share cash tender pulled in some 51.5 million shares, for about $198.2 million, Laborie said April 21. The deal represents a 14.2% premium over CGNT stock’s $3.37 closing price March 9, the last business day before the deal was announced. “Our combined, complementary pr...
Source: Mass Device - April 23, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Women's Health Cogentix Medical Laborie Medical Technologies Source Type: news

Medical News Today: How many times a day should a person pee?
A person will usually urinate more frequently at certain times of day and when they are well hydrated. However, some medical conditions cause a person to pee too often or not often enough. Pregnancy and advancing age can also play a role. Here, learn what causes irregular or frequent urination and how to manage it. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2018 Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news

Medical News Today: Is it safe to hold your pee? Five possible complications
It is usually best to go to the bathroom when the urge hits, but sometimes life gets in the way. Here, learn about the possible complications of holding in pee, including urinary tract infections, damaged pelvic floor muscles, cramping, kidney stones, and more. We also discuss tips for reaching a toilet in time. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 5, 2018 Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news

Medical News Today: What causes urine leakage while coughing?
Peeing while coughing is a form of stress incontinence. It can happen to men and women and is associated with physical activity, such as running or jumping, when pressure is put on the bladder and urine is released unintentionally. Learn about this condition here, including causes, management, and what to do. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 29, 2018 Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news

Herbal blend that includes horsetail found to reduce urinary incontinence and overactive bladder, without the side effects of prescriptions
(Natural News) If you suffer from urinary incontinence or overactive bladder, you’re probably losing patience with the frequent bathroom visits and night awakenings this condition can cause. Perhaps you’ve tried prescription drugs to no avail, or you’re not willing to take on their risks. Now, evidence shows that an herbal blend containing horsetail could help... (Source: NaturalNews.com)
Source: NaturalNews.com - March 15, 2018 Category: Consumer Health News Source Type: news

Laborie Set to Acquire Cogentix
Laborie Medical Technologies is set to acquire Cogentix Medical for about $239 million in a deal that will close in the second quarter of 2018. The price represents a 28% premium over Cogentix average 30-day closing price. Minnetonka, MN-based Cogentix specializes in urology devices. The firm’s products include Urgent PC, a neuromodulation system for percutaneous tibial nerve stimulation. It treats overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence on an outpatient basis. Join us at the BIOMEDevice Boston Expo,  April 18–19, 2018. Use promo code "MD...
Source: MDDI - March 13, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Laborie Medical to pay $214m for Cogentix
Laborie Medical Technologies said today that it agreed to pay $214 million for Cogentix Medical (NSDQ:CGNT) and its line of urology and gynecology devices. Formed by the 2015 merger of Vision-Sciences and Uroplasty, Minnetonka, Minn.-based Cogentix makes the Urgent PC neuromodulation device for treating overactive bladder syndrome, the PrsimeSight cystoscopy and EndoSheath devices and Macroplastique, an injectable soft-tissue bulking agent for treating female stress urinary incontinence. The $3.85-per share cash offer is slated to close during the first half of the year, Toronto-based Lab...
Source: Mass Device - March 12, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Women's Health Cogentix Medical Laborie Medical Technologies Source Type: news

Valencia Tech wins FDA nod for eCoin neurostim overactive bladder trial
Valencia Technologies said today it won FDA investigational device exemption approval to launch a pivotal trial of its eCoin neurostimulation device exploring its ability to treat overactive bladder. The system, which is approximately the size of a nickel, is designed to implanted in a 10 minute procedure and send electrical impulses to the tibial nerve to stimulate the part of the brain that controls bladder response, the New York-based company said. “There is great excitement for a therapy that delivers more than modest improvement in overactive bladder symptoms while avoiding the side-effects of drugs,”...
Source: Mass Device - March 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Valencia Technologies Source Type: news

FDA Approves Pivotal Clinical Trial for Technology to Treat Overactive Bladder
NEW YORK, March 9, 2018 -- (Healthcare Sales & Marketing Network) -- Yesterday, the FDA approved the conduct of a pivotal clinical trial using a new technology to treat overactive bladder. The technology, developed and manufactured by Valencia Technologie... Devices, Urology, FDA Valencia Technologies, overactive bladder, eCoin , neuromodulation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2018 Category: Pharmaceuticals Source Type: news

StimGuard launches head-to-head trial against Medtronic ’ s InterStim
StimGuard yesterday announced plans for a clinical trial comparing its nerve stimulator with the InterStim sacral nerve stimulator made by Medtronic (NYSE:MDT). Pompano Beach, Fla.-based StimGuard is already running a pivotal study of its technology, a miniature implantable device designed to treat urinary incontinence resulting from refractory overactive bladder syndrome. The device is implanted at the tibial nerve through a needle-sized introducer and uses wireless technology to stimulate the nerve. The new study is designed to compare that treatment with InterStim sacral nerve stimulation therapy, which i...
Source: Mass Device - March 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Urology Women's Health Medtronic StimGuard Source Type: news

Overactive bladder treatment may also lead to better sleep
(Reuters Health) - Women with overactive bladder who take medication to address the problem may feel the urge to urinate less often and also sleep better at night as a result, a U.S. study suggests. (Source: Reuters: Health)
Source: Reuters: Health - February 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

5 medtech stories we missed this week: Jan. 26, 2018
[Image from unsplash.com]From Attune Medical receiving FDA 510(k) clearance to Synapse Medical having CE Mark approval, here are 5 medtech stories we missed this week but thought were still worth mentioning. 1. Attune Medical gets FDA 510(k) clearance Attune Medical announced in a Jan. 8 press release that it has received FDA 510(k) clearance for its EnsoETM model that administers tube feeds or medication while cooling or warming patients. The device manages a patient’s temperature through the esophagus while allowing for enteral fluid administration with the company’s ENFit connector. 2. Ally Bridge, Life...
Source: Mass Device - January 26, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Food & Drug Administration (FDA) Hospital Care Neuromodulation/Neurostimulation Regulatory/Compliance Respiratory Ally Bridge Group Attune Medical Axonics Modulation Technologies LifeTech Scientific Corp. MedTech ResMed Inc. Source Type: news

Axonics touts first patients treated in sacral neuromod study
Axonics Modulation Technologies said today that the first 11 patients in its Artisan-SNM sacral neuromodulation study have been implanted with the company’s device designed to treat urinary and bowel dysfunction. The patients were implanted at four centers across the US and Western Europe, the Irvine, Calif.-based company said. The trial will look to enroll 120 patients across 15 centers in total. The single-arm, prospective pivotal study, which won FDA approval last November, is examining the safety and effectiveness of the r-SNM system as an aid to treating urinary urgency incontinence with patients who failed...
Source: Mass Device - January 3, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blog Axonics Modulation Technologies Source Type: news

Cogentix touts MAC coverage extension for OAB neuromod treatment
Cogentix Medical (NASDAQ: CGNT) said today that Medicare Administrative Contractor Palmetto GBA extended granted coverage for percutaneous tibial nerve stimulation procedures to treat overactive bladder with the company’s PC Neuromod System. With the extension, patients with Medicare coverage in North Carolina, South Carolina, parts of Virginia and West Virginia will be eligible to receive PTNS therapy for up to 3 years, adding an additional year onto previous coverage, the Minneapolis, Minn.-based company said. “On behalf of the many overactive bladder patients who can benefit from Urgent PC&rsq...
Source: Mass Device - December 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology Cogentix Medical Source Type: news

Outpost Medicine Appoints Scott Byrd as Chief Executive Officer and Raises $20 Million in Series A Financing Extension
New Investor Takeda Ventures Joins Syndicate; Proceeds to Fund Lead Clinical Stage Program for the Treatment of Overactive Bladder and Irritable Bowel Syndrome INDIANAPOLIS and LONDON, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Outpost ... Biopharmaceuticals, Venture Capital, Personnel Outpost Medicine, Irritable Bowel Syndrome, Overactive Bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Axonics IDE trial for r-SNM neuromod
Axonics Modulation Technologies said today it won FDA investigational device exemption clearance to engage in a pivotal study of its r-SNM rechargeable sacral neuromodulation system designed for treating overactive bladder and bowel dysfunction. The Irvine, Calif.-based company said it expects to begin enrolling patients in the clinical study in November, aiming to enlist 120 patients at 15 centers in the US and Western Europe. “During 2017, as part of the IDE process, the FDA conducted a significant review of our product. A major focus of the technical review was the long-term safety of our implant. The fact th...
Source: Mass Device - November 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Axonics Modulation Technologies Source Type: news

Digging For Gold
This article appeared in the most recent edition of our specialist publication,Trends in Medical Affairs.Click here to download a copy.   Related Content: Pragmatic Trials: The Real-World Data RevolutionNavigating The New LandscapeWhen Real-World Evidence met Patient-CentricityBig Data, Huge OpportunityPrimary Event: Medical Affairs Europe 2018Pr écis: As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?Premium`: Freemium`: Channels: CommercialTags: medical affairsChannelimage:  (Source: EyeForPharma)
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Digging For Gold
This article appeared in the most recent edition of our specialist publication,Trends in Medical Affairs.Click here to download a copy.   Related Content: Pragmatic Trials: The Real-World Data RevolutionNavigating The New LandscapeWhen Real-World Evidence met Patient-CentricityBig Data, Huge OpportunityPrimary Event: Medical Affairs Europe 2018Pr écis: As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?Premium`: Freemium`: Channels: Patients and MedicalTags: medical affairsChannelimage:  (Source: EyeForPharma)
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Prostate problem? Take 2 nuts
By age 60, you have a 50/50 chance of having a clinically enlarged prostate. And it only gets worse every year. When your prostate isn’t functioning properly, it’s hard to enjoy life. Traditional doctors give you two choices. Go under the knife or you take Big Pharma’s drugs. Either way, you have a good chance of ending up with your manhood on the line… If you have surgery, there’s a big risk you’ll be saying goodbye to your sex life for good. The rate of impotence is a shocking 50 to 60% after prostate surgery.1 Big Pharma’s meds to shrink your prostate are no better. These sy...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Are your medications affecting your memory?
Many of today’s most popular drugs can make you forgetful. They inhibit your brain’s chemical messengers. And this blocks your concentration, memory and ability to focus. More specifically, these drugs block the activity of a neurotransmitter in your brain called acetylcholine. Acetylcholine is directly involved in learning and memory. And blocking it is a risky business… I’ve seen confusion, memory loss, and declining mental skills in patients who take these drugs. New research confirms what I see in my own practice. One recent study found that people taking these kinds of drugs had shrunken ar...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Cogentix backs Vensica Medical and its needle-free drug delivery system
Cogentix Medical (NASDAQ: CGNT) said today that it invested $2 million in privately-held Vensica Medical and its ultrasound-based, needle-free drug delivery device, VensiCare. Israel-based Vensica Medical is developing its VensiCare device as a way to deliver botulinum toxin to treat overactive bladder. The company also has IP for the delivery of oncology agents to the bladder, according to Cogentix. Get the full story at our sister site, Drug Delivery Business News. The post Cogentix backs Vensica Medical and its needle-free drug delivery system appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 28, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Wall Street Beat Cogentix Medical vensicamedical Source Type: news

Tackling bedwetting: ‘Don’t be afraid to talk about it’
Bedwetting, otherwise known as urinary incontinence or enuresis, is fairly common, often embarrassing and sometimes difficult to talk about. It is estimated that about 20 percent of boys and 17 percent of girls, ages 6 to 7 years old have some problem with daytime or nighttime wetting. Still, many kids are reluctant to talk about wetting with parents, friends and teachers. Parents themselves often have a hard time confronting the issue. The Voiding Improvement Program (VIP) at Boston Children’s Hospital offers a comprehensive approach to bedwetting tailored to each child’s individual needs. &ldqu...
Source: Thrive, Children's Hospital Boston - August 7, 2017 Category: Pediatrics Authors: Maureen McCarthy Tags: Health & Wellness bedwetting Dr. Carlos Estrada enuresis Pamela Kelly Voiding Improvement Program Source Type: news

Boston Scientific joins OAB device dev Amphora Medical ’ s $36m Series B
Amphora Medical said today it closed a $35.5 million Series B financing round, led by major medtech player Boston Scientific (NYSE:BSX), with funds slated to support a US pivotal trial of its Selective Bladder Denervation System for treating women with overactive bladder. Amphora’s Selective Bladder Denervation System is a minimally-invasive, cystopic device which uses targeted ablation to reduce nerve signals responsible for OAB symptoms at their source without harming nerves responsible for normal bladder function, the Minneapolis, Minn.-based company said. “The closing of this round is an important mile...
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology Women's Health Amphora Medical Boston Scientific Source Type: news

Boston Scientific joins in $36M round for Twin Cities med-tech startup
Amphora Medical Inc. is developing a device to treat overactive bladder and will put the capital toward a clinical trial. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 21, 2017 Category: Health Management Authors: Katharine Grayson Source Type: news

Boston Scientific joins in $36M round for Twin Cities med-tech startup
Amphora Medical Inc. is developing a device to treat overactive bladder and will put the capital toward a clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 21, 2017 Category: Biotechnology Authors: Katharine Grayson Source Type: news

The Role of the Female Urinary Microbiota in OAB Symptoms The Role of the Female Urinary Microbiota in OAB Symptoms
New research suggests a possible link between the microbiota of the female urinary tract and overactive bladder symptoms. What are the implications for urine culturing practices?Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2017 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

MassDevice.com +5 | The top 5 medtech stories for July 17, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. OrthoSensor raises $6.3m OrthoSensor raised $6.3 million in a new round of mixed financing, according to an SEC filing posted this week. Money in the round came from 15 unnamed sources, according to the SEC filing, with the 1st...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Medtronic touts 5-year data on InterStim neuromod device for OAB
Medtronic (NYSE:MDT) today touted 5-year results from the InSite study of its InterStim neuromodulation treatment for overactive bladder syndrome. InterStim is designed to stimulate the sacral nerve to treat OAB, meaning urinary urge incontinence and/or urgency-frequency. The InSite study enrolled 340 patients, of which 272 were implanted with an InterStim device, comparing treatment with the device with standard drug therapy. The primary safety endpoint was to “demonstrate that the upper bound of the 95% CI for the cumulative five-year rate of adverse events related to the tined lead that require surgery is les...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Urology Women's Health Medtronic Source Type: news

Axonics adds $21m to Series C round
Axonics Modulation Technologies said today that it put another $21 million in its coffers in the second tranche of a Series C round for its sacral nerve modulation technology in treating overactive bladder syndrome. The first, $15 million Series C tranche closed in May. The latest, $20.5 million tranche takes Axonics’ total raise to at least $106.1 million, adding to its $32.6 million Series A round and the $38.5 million Series B. The Irvine, Calif.-based company said it plans to use the proceeds on a pivotal study that’s slated to launch late this year. The Series C second tranche included ...
Source: Mass Device - July 6, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

USFDA gives nod to Zydus Cadila's overactive bladder tablets
The drug is used to take care of an overactive bladder and urinary incontinence and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 28, 2017 Category: Pharmaceuticals Source Type: news

Glenmark Pharma's overactive bladder drug gets USFDA nod
According to IMS Health April 2017 sales data, the market for Vesicare tablets, 5 mg and 10 mg, saw annual sales of approximately USD 1.1 billion. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 22, 2017 Category: Pharmaceuticals Source Type: news

Stop an overactive bladder with these 7 herbs and supplements
(Natural News) Guidelines developed by the American Urological Association call for lifestyle and behavioral changes as primary treatments for an overactive bladder. People with an overactive bladder should opt for natural remedies such as dietary changes and fluid management. Patients may also try learning bladder control techniques such as scheduled, delayed, and double-void urination. The guidelines... (Source: NaturalNews.com)
Source: NaturalNews.com - May 11, 2017 Category: Consumer Health News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 2, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Advanced Cardiac Therapies lands $45m round led by new PE shop Ajax Health Ajax Health, the medical device portfolio management company newly formed by KKR and Aisling Capital, led a $45 million round for Advanced Cardiac Thera...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Axonics raises another $15m for U.S. sacral neurostim trial
Axonics Modulation Technologies said today that it put nearly $15 million into its coffers as it readies a pivotal study later this year for its sacral nerve modulation technology in treating overactive bladder syndrome. The Irvine, Calif.-based company said it hopes to add another $15.5 million to the $14.5 million it pulled in from its Series C round, which involved all of its major backers including Edmond de Rothschild Investment Partners, Advent Life Sciences, Cormorant Asset Management, Legend Capital, NeoMed Management and “a select group of private individuals.” “These world-cl...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

Medical News Today: How to treat an overactive bladder with natural remedies
In this article, learn about the symptoms of an overactive bladder, when a doctor should be consulted, and natural remedies to treat an overactive bladder. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 24, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Medical News Today: Overactive bladder in children: Causes, symptoms, and treatment
Learn about the factors that can lead to an overactive bladder in children. What are the signs and when should treatment be given for this condition? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 18, 2017 Category: Consumer Health News Tags: Pediatrics / Children's Health Source Type: news

Medical News Today: Overactive bladder in men: What causes it and how is it treated?
Overactive bladder is a urinary disorder that can affect men and women. What are the causes in men and can lifestyle changes or medical treatments help? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 18, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Depressive Disorders Up With Antimuscarinics for OAB
Increased risk for women with overactive bladder syndrome receiving antimuscarinics (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - April 13, 2017 Category: Psychiatry Tags: Family Medicine, Gynecology, Internal Medicine, Nursing, Pharmacy, Psychiatry, Urology, Journal, Source Type: news

Medical News Today: Best treatments for an overactive bladder
Learn about different treatment options for an overactive bladder, such as dietary and lifestyle changes. Also learn how to monitor an overactive bladder. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Medical News Today: How to manage nocturia: Treating an overactive bladder at night
In this article, we look at the causes of nocturia, which causes frequent urination at night. Learn about how to prevent it and get a good night's sleep. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news